Cargando…
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
Safety and efficacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are limited. The UK National Cancer Research Institute UKALL14 trial NCT01085617 prospectively evaluated the tolerability of 1000 IU/m(2) PEG-ASP administered on days 4 and 18...
Autores principales: | Patel, B, Kirkwood, A A, Dey, A, Marks, D I, McMillan, A K, Menne, T F, Micklewright, L, Patrick, P, Purnell, S, Rowntree, C J, Smith, P, Fielding, A K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154375/ https://www.ncbi.nlm.nih.gov/pubmed/27480385 http://dx.doi.org/10.1038/leu.2016.219 |
Ejemplares similares
-
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study
por: Moorman, Anthony V., et al.
Publicado: (2021) -
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials
por: Creasey, Thomas, et al.
Publicado: (2021) -
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
por: Marks, David I, et al.
Publicado: (2022) -
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
por: Marks, David I, et al.
Publicado: (2022) -
Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol‐E. coli
L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials
por: Sidhu, Jasmeet, et al.
Publicado: (2022)